[Bone mineral density in some lung diseases].

Bone mineral density (BMD) was studied in 93 patients, including 24 patients with nonspecific lung diseases (NLD), 20 with sarcoidosis, 23 with cancer, and 26 with tuberculosis. Among the patients from different groups, the most profound BMD changes were recorded in those with lung cancer. As compared with other groups, the patients of this group were elder and accordingly had many concomitant diseases, which was likely to affect the status of BMD.

[Secretory activity of atrial cardiomyocytes in adrenaline myocardiodystrophy].

Ultrastructure of atrial cardiomyocytes in adrenalin myocardiodystrophy was studied in white rat experiments. Morphometrically, there was a reduced number of mitochondria and secretory granules in the atrial muscular cells, space characteristics of cardiomyocytes and their nuclei increased. The above rearrangement of the atrial cardiomyocytes indicates that adrenalin myocardiodystrophy is associated with a decline in synthetic and secretory function of the test cardiac muscular cells.

[The correction of the hepatotoxicity of antitubercular preparations with tocopherol acetate and riboxin].

It has been established in experiments on white rats that prolonged (for 2 weeks) intoxication with antituberculous drugs (isoniazid plus rifampicin plus pyrazinamide) results in cytolytic liver injury. This manifests by hyperaminotransferasemia, initiation of lipid peroxidation, suppression of the antioxidant system and bile production. Daily injections of tocopherol acetate (15 mg/kg) and riboxine (100 mg/kg) together with administration of antituberculous drugs reduce their hepatotoxicity.

[Effectiveness of tocopherol and anti-hypoxic agents in liver damage caused by antitubercular agents].

Two-week administration of isoniazid, rifampicin (50 mg/kg and pyrazinamide (1,5 g/kg) to white rats brings about liver affection characterized by a higher activity of alanine and aspartate aminotransferases, lipid peroxidation activation and bile production inhibition. With the liver affected by antituberculous drugs, protective action is provided by acetate tocopherol an antioxidant, and piracetam riboxin and pyriditol, antihypoxic agents.

[Clinical and laboratory studies in patients with pulmonary tuberculosis treated with pyrazinamide].

Different combinations of tuberculostatic drugs containing pyrazinamide were prescribed to 144 patients with pulmonary tuberculosis. In 3 months of treatment, bacterial excretion was observed in 89.7% of newly diagnosed patients and in 59% of cases with chronic forms of pulmonary tuberculosis.

[Comparative characterization of the hepatotoxicity of isoniazid, rifampicin and pyrazinamide].

In experiments of rats it was established that administration of isoniazid and rifampicin in equimolecular doses (50 and 250 mg/kg) for 14 days increased the activities of alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase in the serum, enhanced lipid peroxidation in hepatocytic membranes, caused significant disturbances of bile excretion. Pyrazinamide administered in an equimolecular dose (45 mg/kg) moderately suppresses bile excretion and exerts no effect on the activity of the liver enzymes in the serum and the level of lipid peroxidation.

[Hepatotoxic effect of a combination of pyrazinamide with isoniazid and rifampicin].

Experiments on rats showed that 14-day exposure of the animals to pyrazinamide in a dose of 1.5 g/kg induced marked disorders in cholopoiesis and lowering of the reduced glutathion levels in the liver. When pyrazinamide was used in combination with isoniazid or rifampicin a marked increase in the activity of aspartate and alanine aminotransferases in blood serum and induction of lipid peroxidation in the liver were observed in addition to the disorders in cholopoiesis and lowering of the reduced glutathion levels.